Moffitt Cancer Center Cell Coast Conference 2024

Description

+ Include: 15 videos + 15 audios + 15 file sub vtt + 17 pdfs, size: 5.99 GB

+ Target Audience: medical oncologists, hematologists, cellular therapy specialists

+ Sample video: contact me for sample video

+ Information:

Held in the fall of 2024, this conference was launched to spotlight the rapid evolution of cellular therapies, including CAR T-cell therapy, Tumor-Infiltrating Lymphocytes (TILs), and T-cell Receptor (TCR) therapies. The event, themed “Spotlight Breakthroughs in Cellular Immunotherapy,” focused on operationalizing these complex treatments for broader patient access. It provided a unique forum for discussing “real-world” data—moving beyond the controlled environment of clinical trials to examine how these therapies perform in standard clinical settings for both hematologic and solid tumor malignancies.

+ What You Will Learn

Attendees were able to:

• Evaluate real-world outcomes of CAR T-cell therapy in Multiple Myeloma and Lymphoma, comparing them to pivotal trial data.

• Assess the operational challenges of delivering TIL therapy for metastatic melanoma and its emerging role in lung cancer.

• Identify strategies for managing unique toxicities associated with bispecific antibodies and cellular products, such as Cytokine Release Syndrome (CRS) and neurotoxicity.

• Discuss the integration of community oncologists with academic cellular therapy centers to streamline patient referrals and long-term follow-up.

• Examine the potential of TCR therapies for solid tumors, specifically reviewing the FDA approval of afamitresgene autoleucel for synovial sarcoma.

• Analyze the logistics of “Point of Care” CAR T manufacturing and its potential to reduce costs and wait times.

+ Event Details

• Date: October 2024 (Inaugural Event)

• Location: Moffitt Cancer Center, Tampa, Florida

+ Who Should Attend

The conference was designed for the broad oncology community involved in advanced cancer care:

• Medical Oncologists (Academic and Community-based)

• Hematologists

• Cellular Therapy Specialists

• Research Scientists

• Nurses and Advanced Practice Providers managing immunotherapy patients

• Pharmacists

+ Why Attend

• Inaugural Energy: As the first event of its kind from Moffitt, it set the stage for a new “Cell Coast” hub of innovation, offering unique networking with the leaders who pioneered TIL therapy.

• Solid Tumor Focus: Unlike many cell therapy meetings that focus solely on blood cancers, this conference placed significant emphasis on the “next frontier”—treating solid tumors like lung cancer and sarcoma with engineered cells.

• Practical Operations: The agenda included dedicated sessions on “Operational Readiness,” addressing the business and logistical hurdles (e.g., bed capacity, manufacturing delays) that clinics face when adopting these therapies.

 

+ Topics:

• Updates on Approved CAR-T for Lymphoma
• CAR-T for ALL
• CAR-T Strategies for Multiple Myeloma
• Bi-specifics for Myeloma
• Cellular Therapies for Myeloid Malignancies
• Melanoma TILs
• Surgical Considerations for TIL Procurement
• Novel Cell Therapies for Thoracic Malignancies
• Afami-cel TCR for Sarcoma
• Intravesical TIL for Bladder Cancer
• Point of Care CAR T Manufacturing
• Real World CAR-T for Multiple Myeloma
• Infections Occurring in our ICE T Patient Population
• CAR-T in Autoimmune Diseases
• NK Cellular Therapies
• Business Operations of Cellular Therapies